Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated

Recurrent Rectal Cancer Clinical Trial

Official title:

Phase III Trial of Bevacizumab (NSC 704865), Oxaliplatin (NSC 266046), Fluorouracil and Leucovorin Versus Oxaliplatin, Fluorouracil and Leucovorin Versus Bevacizumab Alone in Previously Treated Patients With Advanced Colorectal Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00025337
• Other study ID #: NCI-2012-02417
• Secondary ID: E3200U10CA021115
• Status: Completed
• Phase: Phase 3
• First received: October 11, 2001
• Last updated: January 23, 2013
• Start date: September 2001

Study information

• Verified date: January 2013
• Source: National Cancer Institute (NCI)
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bevacizumab in treating patients who have advanced or metastatic colorectal cancer that has been previously treated. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as bevacizumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining monoclonal antibody therapy with combination chemotherapy may kill more tumor cells. It is not yet known if bevacizumab is more effective with or without combination chemotherapy in treating colorectal cancer

Description:

OBJECTIVES:

I. Compare the response, time to progression, and overall survival of patients with previously treated advanced or metastatic colorectal adenocarcinoma treated with oxaliplatin, leucovorin calcium, and fluorouracil with or without bevacizumab versus bevacizumab only. (Arm III closed to accrual as of 03/11/2003).

II. Compare the toxicity of these regimens in these patients.

OUTLINE: This is a randomized study. Patients are stratified according to ECOG performance status (0 vs 1 or 2), and prior radiotherapy (yes vs no). Patients are randomized to 1 of 3 treatment arms.

Arm I: Patients receive bevacizumab IV over 30-90 minutes and oxaliplatin IV over 2 hours on day 1. Patients also receive leucovorin calcium IV over 2 hours and fluorouracil (5-FU) IV over 22 hours on days 1 and 2.

Arm II: Patients receive oxaliplatin, leucovorin calcium, and 5-FU as in arm I.

Arm III: Patients receive bevacizumab as in arm I. (Arm closed to accrual as of 03/11/2003).

Courses in all arms repeat every 2 weeks in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response may receive 2 additional courses.

Patients are followed every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 880
• Est. primary completion date: April 2007
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Histologically confirmed adenocarcinoma of the colon or rectum

• Advanced or metastatic disease

• Must have received a fluoropyrimidine-based regimen and an irinotecan-based regimen, either alone or in combination, for advanced disease

• May have relapsed within 6 months of adjuvant therapy with fluorouracil (5-FU) (or combination 5-FU and irinotecan) and progressed after single-agent irinotecan

• Measurable disease

• No known brain metastases

• Performance status - ECOG 0-2

• Absolute neutrophil count at least 1,500/mm^3

• Platelet count at least 100,000/mm^3

• No history of thrombotic or hemorrhagic disorders

• Bilirubin no greater than 1.5 times upper limit of normal (ULN)

• AST no greater than 5 times ULN

• INR no greater than 1.5

• PTT no greater than ULN

• Creatinine no greater than 1.5 times ULN

• Proteinuria less than 1+ (i.e., 0 or trace)

• Protein less than 500 mg by 24-hour urine collection

• Proteinuria secondary to ureteral stents allowed

• No proteinuria secondary to nephropathy

• Controlled hypertension (less than 150/100 mm Hg) allowed if on a stable antihypertensive regimen

• No prior myocardial infarction

• No uncontrolled congestive heart failure

• No unstable angina within the past 3 months

• No serious nonhealing wound, ulcer, or bone fracture

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No prior bevacizumab

• See Disease Characteristics

• Recovered from prior chemotherapy

• No prior oxaliplatin

• At least 2 weeks since prior radiotherapy and recovered

• At least 28 days since prior major surgical procedure

• At least 10 days since prior aspirin dose of more than 325 mg/day

• No concurrent therapeutic anticoagulation except prophylactic anticoagulation of venous access device

• No concurrent antiplatelet agents (e.g., dipyridamole, ticlopidine, clopidogrel, or cilostazol)

• No concurrent oral cryotherapy on day 1 of oxaliplatin administration

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adenocarcinoma
• Adenocarcinoma of the Colon
• Adenocarcinoma of the Rectum
• Colorectal Neoplasms
• Rectal Neoplasms
• Recurrent Colon Cancer
• Recurrent Rectal Cancer
• Stage III Colon Cancer
• Stage III Rectal Cancer
• Stage IV Colon Cancer
• Stage IV Rectal Cancer

Intervention

Biological:
• bevacizumab
Given IV

Drug:
• oxaliplatin
Given IV
• leucovorin calcium
Given IV
• fluorouracil
Given IV

Locations

Country	Name	City	State
United States	Eastern Cooperative Oncology Group	Boston	Massachusetts

Sponsors (1)

Lead Sponsor	Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival		From the date of entry on study, assessed up to 5 years	No
Secondary	Response defined using RECIST criteria		Up to 5 years	No
Secondary	Progression free survival		From the date of entry on the study to the appearance of new metastatic lesions or objective tumor progression, assessed up to 5 years	No